MedTrace Logo

Effect of Oligopin® on Blood Pressure.

NCT02063477 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-02-28

No results posted yet for this study

Summary

The objective of the study is to evaluate the effect of consumption of a food supplement rich in procyanidins extracted from the bark of French pine, Oligopin®, on blood pressure of people with mild / moderate degree of hypertension. Furthermore, the effect Oligopin® consumption on markers involved in the development of hypertension, and endothelial function in key enzymes that regulate blood pressure, inflammation and oxidation are considered. Also, try to advance the understanding of the molecular mechanisms that regulate blood pressure.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule

DIETARY_SUPPLEMENT

Oligopin®

Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition: \- TOTAL POLYPHENOL CONTENT \> 96 1. MONOMERS + PHENOLIC ACIDS 30 2. DIMERS \>15 3. OTHER OLIGOMERS 50 PROCYANIDINS CONTENT (GPC) \> 67 The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule

Sponsors & Collaborators

  • Technological Centre of Nutrition and Health, Spain

    lead OTHER

Principal Investigators

  • Rosa M VALLS, PhD · University Rovira i Virgili

  • Rosa SOLÀ, MD,PhD · Hospital Universitari Sant Joan, Universitat Rovira i Virgili, CTNS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063477 on ClinicalTrials.gov